Entry Point Capital, LLC Xeris Biopharma Holdings, Inc. Transaction History
Entry Point Capital, LLC
- $246 Million
- Q3 2025
A detailed history of Entry Point Capital, LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 53,015 shares of XERS stock, worth $384,358. This represents 0.17% of its overall portfolio holdings.
Number of Shares
53,015
Previous 72,899
27.28%
Holding current value
$384,358
Previous $340,000
26.18%
% of portfolio
0.17%
Previous 0.18%
Shares
6 transactions
Others Institutions Holding XERS
# of Institutions
236Shares Held
94.1MCall Options Held
251KPut Options Held
61.8K-
Black Rock Inc. New York, NY10.3MShares$74.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.83MShares$71.3 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.84MShares$42.3 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA4.14MShares$30 Million0.0% of portfolio
-
State Street Corp Boston, MA3.74MShares$27.1 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $986M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...